AstraZeneca partners with Oracle for AI-driven clinical trials
The non-binding agreement will test AI tools to find eligible patients earlier and speed evidence generation across trial and care workflows.
- On Tuesday, October 20, 2026, AstraZeneca announced a collaboration with Oracle to use artificial intelligence and real-world data to accelerate clinical research and improve patient recruitment for trials.
- Patient recruitment remains a primary challenge in clinical research, as delayed enrollment extends development timelines and increases costs, prompting AstraZeneca to address past trial design failures.
- The first project will support hypertension research in Abu Dhabi through a partnership with healthcare firm M42. Chief Executive Officer Pascal Soriot said the collaboration brings "leaders in healthcare and AI together at a global scale."
- Combining AstraZeneca's drug development expertise with Oracle's cloud and analytics capabilities, the partnership aims to help clinicians identify eligible patients sooner. Seema Verma, executive vice president of Oracle Health and Life Sciences, said progress depends on "shortening the distance between scientific insight and the decisions clinicians make every day."
- AstraZeneca intends to expand its medicine portfolio, targeting over $80 billion in annual revenue by 2030. Chief Digital, Data and AI Officer Anne-Claire Gerbaldi noted the technology aims to address care gaps where patients face long diagnostic journeys.
39 Articles
39 Articles
Oracle is pursuing a plan with AstraZeneca to leverage artificial intelligence (AI) and real-world data (RWD) to identify patients suitable for clinical trials and connect research outcomes to clinical practice. Oracle announced on the 21st that it had signed a non-binding agreement with AstraZeneca containing these details. The two companies are exploring the potential of AI and the latest applications, focusing on reducing the time and burden …
AstraZeneca and Oracle team up on AI to find patients for drug trials
AstraZeneca and Oracle will use AI and real patient health data to find people for drug trials faster, the two firms announced. The deal adds to a long list of AI health tie-ups between drugmakers and tech companies. The pair signed a non-binding term sheet, so the terms are not yet final, and neither firm said or […] This story continues at The Next Web
AstraZeneca partners with Oracle for AI-driven clinical trials
AstraZeneca said on Tuesday that it is working with Oracle to use AI and real-world data to identify eligible patients for clinical trials and monitor safety signals, among other measures, as the drugmaker looks to improve clinical research.
AstraZeneca, Oracle to launch their first global AI program in Abu Dhabi: CEO
AstraZeneca and Oracle team up on AI, aiming to speed up clinical trials and improve patient care pathways, with the first programme set for Abu Dhabi in partnership with M42. CNBC's Dan Murphy speaks to AstraZeneca's CEO Pascal Soriot live from the sidelines of the Future Health Summit in Abu Dhabi.
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium




















